Ataraxis Unveils Causal AI Model, Raises $20.4M Series A

Ataraxis launched its causal multimodal AI model CTX with three preprints and a $20.4M Series A, predicting counterfactual chemotherapy outcomes, and achieving zero-shot generalization from breast cancer to multiple solid tumors.

2026-09-14 ~ 2026-09-15 · 2 related posts

• Ataraxis launches causal multimodal AI predicting chemo benefit, raises $20.4M Series A — multiply_matrix · 2026-09-14
• Ataraxis Debuts Causal AI That Predicts Cancer Treatment Outcomes Zero-Shot — multiply_matrix · 2026-09-15